SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  
From: tnsaf3/9/2021 12:47:39 PM
   of 3661
 
GRAY -45% Point 4 is the likely torpedo
  1. Median time to first supportive therapy was 5 months for GB-102 1mg
  2. 48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 months
  3. Control of retinal thickness was consistent across all trial arms
  4. Mean best-corrected visual acuity with GB-102 1mg trended lower than aflibercept arm
  5. No drug-related serious adverse events
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News